Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $526.6 million.

  • Ligand Pharmaceuticals' Total Liabilities rose 36319.84% to $526.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $526.6 million, marking a year-over-year increase of 36319.84%. This contributed to the annual value of $111.3 million for FY2024, which is 2900.48% up from last year.
  • Ligand Pharmaceuticals' Total Liabilities amounted to $526.6 million in Q3 2025, which was up 36319.84% from $120.1 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Total Liabilities peaked at $549.3 million during Q1 2021, and registered a low of $86.3 million during Q4 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' median Total Liabilities value was $164.8 million (recorded in 2023), while the average stood at $240.4 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 6597.11% in 2023, then soared by 36319.84% in 2025.
  • Ligand Pharmaceuticals' Total Liabilities (Quarter) stood at $476.4 million in 2021, then plummeted by 65.33% to $165.2 million in 2022, then plummeted by 47.75% to $86.3 million in 2023, then grew by 29.0% to $111.3 million in 2024, then skyrocketed by 372.99% to $526.6 million in 2025.
  • Its last three reported values are $526.6 million in Q3 2025, $120.1 million for Q2 2025, and $109.9 million during Q1 2025.